Immunohistochemistry analysis of Pax-5 showing positive staining in the nucleus of paraffin-treated Human tonsil tissue (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a Pax-5 monoclonal antibody (Product # MA5-14585) diluted by 3% BSA-PBS at a dilution of 1:20 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from the C-terminus of human Pax-5 protein|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:10-1:500|
|Western Blot (WB)||1:10-1:500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 2 publications below|
MA5-14585 targets Pax-5 in IHC (P) and Western blot applications and shows reactivity with Human and Mouse samples.
The MA5-14585 immunogen is synthetic peptide derived from the C-terminus of human Pax-5 protein.
PAX-5 is a B-cell-specific activator protein (BSAP). In the early stages of B cell developmemt, PAX-5 influences the expression of several B-cell-specific genes, such as CD19 and CD20. PAX-5 is expressed primarily in pro-, pre-, and mature B cells, but not in plasma cells. PAX-5 is expressed in most B-cell malignancies (pre-B and mature B cell lymphomas/leukemias). Over 90% of cases are positive for PAX-5 in Hodgkin's lymphoma, lymphoplasmacytic lymphoma, Merkel cell and small cell carcinoma. T-cell lymphomas, myeloma/plasmacytoma and carcinoid tumors are negative for PAX-5.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||
Increased utilization, verification, and clinical implications of immunocytochemistry: Experience in a northern New England hospital.
MA5-14585 was used in immunohistochemistry to study a northern New England hospital and increased utilization, verification, and clinical implications of immunocytochemistry
|Sauter JL,Ambaye AB,Mount SL||Diagnostic cytopathology (43:688)||2015|
Composite lymphoma in the anterior mediastinum: a case report and review of the literature.
MA5-14585 was used in immunohistochemistry to present a case report of an unusual composite lymphoma in the mediastinum
|Yu G,Kong L,Qu G,Zhang Q,Wang W,Jiang L||Diagnostic pathology (6:null)||2011|